Dazodalibep is a CD40 ligand antagonist recently investigated in a phase 2 double-blind trial for the treatment of active moderate-severe rheumatoid arthritis (RA) with inadequate response to disease-modifying anti-rheumatic drugs (NCT04163991). We were delighted to speak to Dr. Alan J. Kivitz (Altoona Center for Clinical Research, Duncansville, PA, USA) to discuss the rationale for investigating dazodalibep in RA and the findings from the phase 2 study.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of Dazodalibep (VIB4920/HZN4920) in Patients with Rheumatoid Arthritis Having Inadequate Response to Conventional/Biological DMARDs.‘ (Abstract number: 2008) was presented at the ACR Convergence, November 10–14, 2022.
- What are the limitations of current disease-modifying anti-rheumatic drugs?
- What is dazodalibep and what is the rationale for its use in patients with rheumatoid arthritis?
- What were the eligibility criteria of your phase 2 study?
- What were the primary and secondary endpoints and how well were they achieved?
- On the basis of current findings, what is the potential of dazodalibep in the treatment paradigm for rheumatoid arthritis?
Disclosures: Alan J. Kivitz has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
Share this Video
Related Videos In Rheumatoid Arthritis
Kevin Winthrop, ACR 2022: Integrated safety analysis of filgotinib in moderately to severely active rheumatoid arthritis
Filgotinib, is an oral Janus kinase 1 inhibitor approved in Europe, Japan, and the UK for the treatment of patients with moderately to severely active rheumatoid arthritis (RA). In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health & Science University, Portland, OR, USA) to discuss the objectives, methodology and findings from […]
Paul Studenic, ACR 2022: A validation study of the revised ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the methodology and findings of the validation […]
Paul Studenic, ACR 2022: The 2022 revision of the ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis (RA) over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the limitations of the Boolean and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!